基于WHO 958号技术报告分析基本药物目录遴选关注重点  

Focus of the Selection of the Essential Drug List from WHO Technical Report Series 958

作　　者：杨悦[1] 李延敏[1] 宁艳阳[1] 王华[1] 罗列[1] 

机构地区：[1]沈阳药科大学工商管理学院,沈阳市110016

出　　处：《中国药房》2011年第32期2981-2983,共3页China Pharmacy

摘　　要：目的:为我国基本药物遴选提供建议。方法:通过对WHO958号技术报告进行介绍,分析WHO基本药物目录遴选的关注重点。结果与结论:我国可通过提高认识、注重合作、完善目录格式、预审厂家资格、关注相关风险等措施来改进基本药物遴选方式。OBJECTIVE：To give suggestions for the selection of the essential drugs in China. METHODS： The focus of the selection of the essential drug list was analyzed from introducing WHO technical report series 958. RESULTS CONCLUSIONS： Our country can improve the essential drugs selecting mode by raising awareness, focusing on cooperation, and improving the format of the essential drug list, pre-qualifying manufacturers, concerning about the associated risks.

关 键 词：世界卫生组织 基本药物 基本药物目录 遴选 

分 类 号：R95[医药卫生—药学]